Immunotherapy has revolutionized the field of oncology by utilizing the body's immune system to target and eliminate cancer cells. In non-small cell lung cancer (NSCLC), immunotherapeutic agents such as immune checkpoint inhibitors (ICIs) have shown promising results. ICIs target receptors like PD-1, PD-L1, and CTLA-4 to enhance the immune response against tumors. However, resistance mechanisms to immunotherapy...